AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04240067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: READ-MA Multimarker Approach
Description: The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
Study NCT04673149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5310
Description: GLS-5310 DNA plasmid vaccine
Study NCT03865017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
Study NCT03865017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline+cell suspension solution infusion
Study NCT02200458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer
Description: Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
Study NCT04673149 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02687373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Study NCT03793855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Strategy
Description: Counseling based on dietary goals and mindfulness techniques.
Study NCT03793855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Prescription
Description: Dietary prescription according to guidelines.
Study NCT00301379 — intervention group
Intervention type: OTHER
Intervention: Observation data collection study.
Description: This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
Study NCT02476643 — intervention group
Intervention type: OTHER
Intervention: Integrative Therapy
Description: This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
Study NCT02860923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT02860923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00233129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Top Down
Description: Six months
Study NCT00233129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive rehabilitation day treatment program
Description: six months
Study NCT03382743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical Lidocaine spray
Description: 5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
Study NCT04514042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy
Description: Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
Study NCT04514042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible endoscopic septotomy
Description: Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
Study NCT00568347 — intervention group
Intervention type: DRUG
Intervention: fluticasone 100mcg/ salmeterol 50mcg
Description: inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
Study NCT00568347 — intervention group
Intervention type: DRUG
Intervention: fluticasone 250/salmeterol 50
Description: inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
Study NCT00568347 — intervention group
Intervention type: DRUG
Intervention: salmeterol
Description: salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
Study NCT00568347 — intervention group
Intervention type: DRUG
Intervention: Salmeterol
Description: salmeterol 50mcg bid X 3months
Study NCT00568347 — intervention group
Intervention type: DRUG
Intervention: salmeterol and fluticasone propionate
Description: salmeterol 50mcg/fluticasone 250mcg by DPI bid
Study NCT02724020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus capsules.
Study NCT02724020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules.
Study NCT02724020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 capsules.
Study NCT02850627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongguan capsule
Description: eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
Study NCT02850627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
Study NCT04311203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid
Description: The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
Study NCT04341298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11-point pain scale
Description: Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
Study NCT04341298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 11-point pain scale
Description: Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
Study NCT04341298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headache diary
Description: Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
Study NCT04341298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Headache diary
Description: Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
Study NCT04341298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avulux®
Description: Avulux® device
Study NCT04341298 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Avulux®
Description: Sham Avulux®
Study NCT01442168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin sodium + atovaquone/proquanil
Description: Sevuparin 4 times per day and malanil according to label
Study NCT01442168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone/proquanil
Description: malanil according to label
Study NCT01238497 — intervention group
Intervention type: DEVICE
Intervention: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Description: Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
Study NCT01238497 — intervention group
Intervention type: DEVICE
Intervention: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Description: Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
Study NCT01238497 — intervention group
Intervention type: DEVICE
Intervention: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Description: Patients eligible for transfemoral access and requiring a 29mm valve.
Study NCT03241498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicines optimisation
Study NCT01688973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: 150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
Study NCT01688973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01688973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: 360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
Study NCT04036240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger feeding
Description: After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
Study NCT04151121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT (Mindfulness Based Cognitive Therapy)
Description: MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
Study NCT00748969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin (DNA origin)
Description: The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
Study NCT01065272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days
Study NCT01065272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days
Study NCT03748160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
Study NCT02687373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study NCT00445627 — intervention group
Intervention type: DRUG
Intervention: Metformin
Study NCT00445627 — intervention group
Intervention type: DRUG
Intervention: Insulin
Study NCT00445627 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nutrition counseling
Study NCT00445627 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise counseling
Study NCT00249483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxiine 300mg/day
Study NCT02793167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKI alert
Study NCT02098317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA plus Vitamin D
Description: DHA 500 mg plus Vitamin D 800 IU
Study NCT01289457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle.
Study NCT02098317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pearls mimicking pearls with DHA and Vitamin D
Study NCT04030481 — intervention group
Intervention type: OTHER
Intervention: inhalation anesthesia
Description: sevoflurane was used to maintain anesthesia
Study NCT04030481 — intervention group
Intervention type: OTHER
Intervention: Total intravenous anesthesia
Description: propofol was used to maintain anesthesia
Study NCT05687201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)
Description: Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
Study NCT03198169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atteris Antimicrobial Skin and Wound Cleanser
Description: Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
Study NCT02196467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myoblast transplantation
Description: 30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
Study NCT00249483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02196467 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
Study NCT02556853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination of tube position by ultrasound.
Description: After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
Study NCT02688361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluimucil® 2% solution
Description: Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
Study NCT02688361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 2% solution
Description: Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
Study NCT03670433 — intervention group
Intervention type: OTHER
Intervention: Cost analysis of medication reconciliation
Description: 1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS.
Study NCT03930511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
Study NCT01390519 — intervention group
Intervention type: OTHER
Intervention: everolimis
Study NCT04007679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
Study NCT02556853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of tube position by auscultation.
Description: After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
Study NCT01289457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
Study NCT01289457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
Study NCT01878435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Study NCT01878435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel subsidy
Study NCT01878435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel subsidy 2
Study NCT00938782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline
Study NCT01522339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDX/GE Electronics
Description: MRI scan(s) for no longer than 60 minutes
Study NCT03633903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
Study NCT03165383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Transversus Abdominis Plane Block)
Description: Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
Study NCT03165383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Patient Controlled Analgesia (PCA) Morphine
Description: PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
Study NCT01883765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback active